# Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease

> **NCT01604213** · PHASE4 · COMPLETED · sponsor: **Sheba Medical Center** · enrollment: 60 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Ischemic Heart Disease

## Interventions

- **DRUG:** Metformin plus vildagliptin
- **DRUG:** Metformin only

## Key facts

- **NCT ID:** NCT01604213
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01604213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01604213, "Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01604213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*